


## Elpamotide

### Chemical Properties

CAS No. :	673478-49-4
Formula:	C47H76N16O13
Molecular Weight:	1073.21
Storage:	Keep away from moisture Powder: -20°C for 3 years   In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



### Biological Description

Description	Elpamotide is a vaccine consisting of a VEGFR2-169 peptide.
Targets(IC50)	VEGFR

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.9318 mL	4.6589 mL	9.3178 mL
5 mM	0.1864 mL	0.9318 mL	1.8636 mL
10 mM	0.0932 mL	0.4659 mL	0.9318 mL
50 mM	0.0186 mL	0.0932 mL	0.1864 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Ottaiano A, Capozzi M, De Divitiis C, De Stefano A, Botti G, Avallone A, Tafuto S. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials. *Acta Oncol.* 2017 Mar;*56*(3):377-383. doi: 10.1080/0284186X.2017.1288922. Epub 2017 Feb 17. Review. PubMed PMID: 28256961.

Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H, Ohkawa S, Furukawa M, Maguchi H, Ikeda M, Togashi Y, Nishio K, Ohashi Y. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. *Cancer Sci.* 2015 Jul;*106*(7):883-90. doi: 10.1111/cas.12674. Epub 2015 May 14. PubMed PMID: 25867139; PubMed Central PMCID: PMC4520640.

Matsuyama M, Ishii H, Furuse J, Ohkawa S, Maguchi H, Mizuno N, Yamaguchi T, Ioka T, Ajiki T, Ikeda M, Hakamada K, Yamamoto M, Yamaue H, Eguchi K, Ichikawa W, Miyazaki M, Ohashi Y, Sasaki Y. Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer. *Invest New Drugs.* 2015 Apr;*33*(2):490-5. doi: 10.1007/s10637-014-0197-z. Epub 2014 Dec 13. PubMed PMID: 25502982; PubMed Central PMCID: PMC4387249.

Okamoto I, Arai T, Miyazaki M, Satoh T, Okamoto K, Tsunoda T, Nishio K, Nakagawa K. Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. *Cancer Sci.* 2012 Dec;*103*(12):2135-8. doi: 10.1111/cas.12014. Epub 2012 Oct 14. PubMed PMID: 22957712.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481